Peptide Database

Showing 10 of 58 peptides

CategoryFDA Status
5-amino-1MQFat loss, metabolic health, NNMT inhibitionWeight LossAnimalNot Approved
0
TirzepatideWeight loss, type 2 diabetes, dual GIP/GLP-1 agonistWeight LossApprovedApproved
1821994 human
RetatrutideWeight loss, triple agonist (GLP-1/GIP/glucagon)Weight LossPhase IIINot Approved
12884 human
AOD-9604Fat metabolism, weight loss, cartilage repairWeight LossPreclinicalCategory 2
1010 human
CagrilintideWeight loss, amylin analog, combined with semaglutideWeight LossPhase IIINot Approved
6942 human
LiraglutideWeight loss, type 2 diabetes, cardiovascular protectionWeight LossApprovedApproved
52743224 human
SurvodutideWeight loss, MASH/NASH liver disease, dual GLP-1/glucagon agonistWeight LossPhase IIIInvestigational
5938 human
SemaglutideWeight loss, type 2 diabetes, cardiovascular risk reductionWeight LossApprovedApproved
43572525 human
MazdutideWeight loss, dual GLP-1/glucagon agonist, Chinese-developed obesity drugWeight LossPhase IIIInvestigational
3723 human
TesofensineWeight loss, triple monoamine reuptake inhibitor, appetite suppressionWeight LossPhase IIInvestigational
5139 human